| Names | |
|---|---|
| Preferred IUPAC name | (1-((2Z)-2-(2-furyl)-2-(methoxyimino)acetyl)-7-[[(2R)-2-(acetoxy)propionyloxy]imino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Other names | Ceftin Zinnat Kefurox Cefuroximax Biofuroksym |
| Pronunciation | /ˌsɛf.jʊˈrɒk.sɪm ækˈsɪt.ɪl/ |
| Identifiers | |
| CAS Number | 64544-07-6 |
| Beilstein Reference | 3196734 |
| ChEBI | CHEBI:51080 |
| ChEMBL | CHEMBL1426 |
| ChemSpider | 187449 |
| DrugBank | DB00657 |
| ECHA InfoCard | ECHA InfoCard: 100.113.527 |
| EC Number | 64952-96-9 |
| Gmelin Reference | 3310101 |
| KEGG | C07432 |
| MeSH | D000831 |
| PubChem CID | 441199 |
| RTECS number | XU7174000 |
| UNII | J36B7POD2B |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID8021883 |
| Properties | |
| Chemical formula | C20H22N4O10S |
| Molar mass | 424.4 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.56 g/cm³ |
| Solubility in water | Practically insoluble in water |
| log P | 0.7 |
| Acidity (pKa) | 2.5 |
| Basicity (pKb) | 8.16 |
| Magnetic susceptibility (χ) | -84.8x10^-6 cm³/mol |
| Refractive index (nD) | 1.619 |
| Dipole moment | 2.5 ± 0.5 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 610.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -970.7 kJ/mol |
| Pharmacology | |
| ATC code | J01DC02 |
| Hazards | |
| Main hazards | May cause allergic reactions, gastrointestinal disturbances, and hypersensitivity; may cause rash, nausea, vomiting, and diarrhea. |
| GHS labelling | GHS07 |
| Pictograms | lactose-free, gluten-free, prescription-only |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Use only as directed by a physician. Store at controlled room temperature, away from moisture and light. |
| Flash point | > 196.2 °C |
| Autoignition temperature | 800°C (1,472°F) |
| Lethal dose or concentration | LD50 (oral, rat): > 5,000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Cefuroxime Axetil: "5 g/kg (oral, in rats) |
| NIOSH | AM8000000 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 750 mg daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Cefuroxime Cefuroxime sodium Cefuroxime lysine Cefuroxime pentaxetil |
| Product Identification | |
|---|---|
| Product Name | Cefuroxime Axetil |
| IUPAC Name | 1-(acetyloxy)ethyl (6R,7R)-3-[(carbamoyloxy)methyl]-7-[2-(fur-2-yl)-2-methoxyiminoacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Chemical Formula | C20H22N4O10S |
| CAS Number | 64544-07-6 |
| Synonyms & Trade Names | Cefuroxime 1-(acetyloxy)ethyl ester; Ceftin; Zinnat; Zinoximor |
| HS Code & Customs Classification |
HS Code: 2941.90 Classification: Antibiotics; other antibiotics |
Technical validation in product identification drives every batch’s compliance in regulated pharmaceutical manufacturing. For Cefuroxime Axetil, selecting raw materials aligns with regulatory and pharmacopeial compliance upstream. Controlled synthesis leverages the axetil moiety to enhance oral bioavailability compared with the parent acid form. This esterification changes not just formulation parameters, but affects logistical workflows throughout handling and downstream processing.
Naming conventions reflect both synthetic complexity and end-market requirements. Selection and verification of synonyms occur in alignment with pharmacovigilance, customs controls, and distribution chain transparency. HS code designation determines export reporting and tariff eligibility; current customs rules place most oral, semi-synthetic cephalosporins under 2941.90, which governs movement into APIs and finished dosage pharmacomarkets. The shift in code assignment influences documentation, tax rates, and requires accurate manifest filing based on final intended use and jurisdiction.
Product identification parameters form part of batch release control and are tied to both internal quality criteria and market-facing documentation. Refinements in naming or code assignment typically drive from regulatory updates, customer requirement shifts, or trade disruptions, which manufacturers review as part of ongoing compliance cycle. Consistency in chemical structure documentation supports rapid dispute resolution, batch traceability, and facilitates customs clearance, which can otherwise delay critical supply chains, especially under tighter global health controls.
Production for regulated pharmaceutical markets usually requires alignment to compendial monographs, with nomenclature reflecting both chemical purity grade and intended formulation route. There can be subtle differences in how each regulatory regime wants the ester detailed in documentation, especially if supplied as micronized powder for formulation or granulated for direct compression. The chemical formula remains stable, but handling, labeling, and final product release must adapt to each grade category issued from production.
In reference to chemical identification, warehouse infrastructure and material tracking software rely on correct CAS, name, and HS codes to allocate inventory into validated storage zones and maintain chain of custody logs. Incorrect coding at point of manufacture or reprocessing can cause rejections at import or regulatory audit, leading to costly delays or product quarantines. For Cefuroxime Axetil, accountability in these details protects the batch from regulatory risk and supports transparent interaction with formulators, auditors, and market regulators.
Cefuroxime Axetil typically appears as a white or off-white crystalline powder. The substance does not exhibit any strong odor at room temperature. Physical form and color may shift slightly between batches, especially when the production route or particle size distribution varies for different pharmaceutical grades. Melting point observations fall within a range set by internal reference standards, reflecting the influence of starting material qualities and purification cycles. Boiling point and flash point are not operationally relevant due to decomposition prior to volatilization under standard laboratory methods. Density measurements are most reliable by pycnometry for processed granules or compacted forms, and are subject to grade-dependent variability.
Cefuroxime Axetil shows sensitivity to moisture and hydrolysis, especially in the presence of water or humid air. Batch stability trends are influenced by residual solvent content, trace acid/base contamination, and packaging method. Contact with strong acids or bases promotes rapid degradation, sometimes visible as color change or caking. Mechanical milling and granulation must avoid excessive heat to limit partial decomposition.
The product is practically insoluble in water, solubilizing only in some organic solvents or in the presence of suitable surfactants. Solubility characteristics depend on particle size, modification of polymorph populations during processing, and specific formulation approaches. Preparation of standard test or application solutions often requires sonication or use of special diluents, as specified per customer formulation need or application pathway.
Specifications shift depending on the application—oral dosage formulations may call for tighter impurity controls and particle size uniformity, while grades for research or intermediate use have broader ranges. Water content, heavy metals, enantiomeric purity, and microbial limits are included in the standard specification profile, but target levels differ per customer registration and region.
| Parameter | Oral Grade | API Grade |
|---|---|---|
| Assay | Defined per internal pharmacopeial references | Defined per pharmacopeia |
| Impurities | Tighter limits for regulated markets | Specified by customer or regulatory body |
| Residual Solvent | Controlled as per ICH Q3C | Grade-dependent |
| Particle Size | Customizable | Process-dependent |
Impurity sources stem mainly from side reactions during esterification and from the cefuroxime base production. Process control focuses on limiting isomeric esters, related cephalosporin analogs, and axetil dimerization products. Internal quality reviews set release criteria for known impurities based on grade and target market, using LC-MS or HPLC methods.
Product testing draws on methods harmonized across pharmacopeias, with adjustments made for region-specific requirements. Wet chemistry, chromatography, Karl Fischer titration, and particle size analysis all feature in lot release records. Each released batch undergoes method validation against reference standards retained in our technical archives.
Key raw materials include cefuroxime acid, axetil alcohol, activating agents, and carefully screened solvents. Raw material suppliers must demonstrate traceability and meet pre-qualification criteria, especially for substances with the greatest impact on impurity profile or product safety.
Synthesis proceeds via esterification of the cefuroxime base with axetil chloride or alternative alkylating agents under controlled pH and temperature to maximize desired isomer yield while suppressing by-product formation. Reaction selection weighs trade-offs between yield, impurity generation, and solvent recyclability, optimizing for both regulatory compliance and environment, health, and safety considerations.
Critical control points include pH stabilization during coupling, temperature management during crystallization, and solvent removal under reduced pressure. Purification steps conventionally employ recrystallization and selective adsorption to minimize persistent impurities. Process flowsheet is periodically revised to address changes in regulatory guidance and to accommodate new impurity discoveries.
Each batch is sampled and tested at defined hold points, with full traceability preserved through batch records. Final lot release depends on conformity to all in-house and agreed external specification limits, supported by certificate-of-analysis documentation. Deviations are reviewed by quality assurance teams, and corrective actions are taken before any material is released to the supply chain.
Cefuroxime Axetil readily hydrolyzes to release active cefuroxime under physiological or acidic conditions. Under basic environment, the axetil ester can saponify, reducing activity. The molecule’s β-lactam ring remains vulnerable to nucleophilic attack, which demands gentle handling through all production and formulation stages.
Manufacturing operates under moderate temperatures to limit degradation. Catalysts for esterification are selected according to trace metal limits and regulatory impact. Solvent choice prioritizes high-purity organic solvents with low water content to preserve product integrity.
Downstream processing may yield other ester analogs or intermediates for broader cephalosporin synthesis. Modification potential depends on the flexibility of the ester moiety and target market’s regulatory position on new chemical entities derived from the parent scaffold.
Ambient storage away from light and humidity preserves stability for most applications. Temperature control can be critical for long-term storage, particularly for packaged bulk material awaiting encapsulation or tableting. Oxygen and moisture barriers on packaging play an essential role in minimizing hydrolysis and maintaining potency over time.
Packaging is selected to avoid interaction with plasticizers, metals, and elastomers—HDPE and glass are preferred where leachables pose a risk. Secondary containment protects against accidental moisture exposure in transit or warehousing.
Shelf life is determined through ongoing stability studies, and batches undergo regular reassessment. Loss of potency or appearance of off-color granulation signals degradation, typically from hydrolysis or oxidative pathways. Shelf life may vary depending on product grade and intended use environment.
Global Harmonized System classification refers to skin sensitization and potential acute effects based on observed exposure data and published literature. Classification may shift as new information becomes available or as regulations evolve in different regions.
Technical review assigns hazard statements covering allergenic and irritation potential. Packaging and workplace instructions state that skin and respiratory exposure should be avoided, and engineering controls must be used to limit dust generation. Emergency procedures align with regional occupational health and safety regulations.
Available toxicity results stem from animal model studies and clinical adverse event histories. Sensitive populations such as penicillin-allergic individuals are mentioned in training and internal safety guidance. Exposure limits comply with jurisdictional requirements, with engineering, monitoring, and PPE controls tuned for high-throughput API production. Personnel are trained to recognize both acute and delayed hypersensitivity reactions.
In recent years, capacity planning for cefuroxime axetil hinges on both 7-ACA and axetil-side chain precursor supply security. Multi-plant setups are often necessary for redundancy, especially when scale-up at each site is limited by filtration throughput and hydrolysis waste recovery. In actual production, yields are highly sensitive to batch integrity; batch-to-batch tracking identifies any deviation in impurity profiles. During high demand cycles, available inventory fluctuates as API release waits on finished product testing and documentation sign-off. Procurement teams actively monitor global precursor shipment trends since disruptions in any major exporting region immediately tighten capacity.
Lead time relies on ongoing campaign production windows, since most plants do not retain pre-packed large lots due to stability and moisture pick-up risk. For customer projects, MOQ depends on grade and certification—pharma-grade typically starts at higher MOQ due to full-batch release requirements, whereas technical grades or non-EU/US orders allow greater flexibility. Production cycle lengths, driven by purification bottlenecks and local regulatory batch-release checks, determine minimum lead time; typically, any unplanned upward swing in orders from major markets lengthens new order fulfillment by several weeks.
The packaging method is defined by both regulatory and downstream handling requirements. Bulk APIs ship in triple-layer PE/AL bags with drum exterior for most regulated markets; custom weights and inert gas blanket become necessary for specific humidity-sensitive applications. For higher-grade or sterile applications, inner packaging integrity receives greater emphasis, with documented container performance subjected to transit simulation and stress-testing before approval.
Shipping adherence follows client-approved GDP protocols, often requiring validated temperature control during transit, especially for tropical destinations. Some clients require data logging throughout transport, adding logistical complexity. L/C or advanced payment terms are industry standard for new clients or higher value lots. Repeat contracts may offer net terms, linked directly to prior performance and in-market credit checks.
Cefuroxime axetil cost structure predominantly tracks two raw material inputs: 7-ACA and specialty intermediates for axetil synthesis. The cost proportion is variable by process route. Fluctuations in global fermentation output for 7-ACA or sudden regulatory issues at upstream API plants trigger sharp price adjustments. High-purity water and specialty solvents also contribute but remain comparatively stable unless international logistics falter. Exchange rate volatility can create short-term swings in offered price, particularly where supply contracts are denominated in USD or EUR.
End-user segment and regulatory status drive most price differences. For example, product released under validated cGMP with full DMF support carries premiums over standard technical grade, reflecting higher analytical burden and increased compliance cost. Required impurity profile standards—dictated by target market pharmacopoeia—impact final cost, since stringent removal of minor related substances lengthens production and testing cycle. For some clients, packaging with anti-counterfeiting features or customized secondary labeling adds a further premium per kilogram.
Global demand for cefuroxime axetil aligns with hospital and outpatient sector usage, particularly in respiratory and urinary tract infection therapy guidelines. Largest consumption concentrates in Asia and Europe, but procurement schedules and stockpiling behaviors in the US and Japan can shift market balance, causing short-term supply pinch. Indian and Chinese producers anchor baseline capacity; regulatory exports from China are susceptible to dual-use intermediate compliance audits, which introduce sudden supply unpredictability.
US and EU clients emphasize traceability, requiring synchronization with local QP (Qualified Person) release practices and origin transparency. In Japan, multi-batch quality equivalency gains focus, with strict adherence to extended impurity monitoring. Indian buyers drive bulk tonnage, frequently prioritizing competitive ex-works pricing and expedited delivery. In China, domestic regulatory shifts—such as new Green Supply Chain standards or mandatory waste solvent recovery—alter local costs and export licensing.
Looking toward 2026, structurally higher costs for solvent recovery, environmental compliance, and additional analytical release criteria—especially in major export hubs—are expected to push up base prices, unless there is a major breakthrough in synthetic process efficiency or alternate intermediate sourcing. Price volatility is predicted to persist, largely due to upstream fermentation cycle unpredictability and global regulatory tightening. On the other side, process intensification and continuous manufacturing initiatives may eventually dampen long-term cost inflation for high-volume, lower-grade orders.
Market pricing and supply analysis integrates data from internal production records, confidential customer inquiry logs, indices from leading pharmaceutical input agencies, and cross-industry compliance alerts. Price trend forecasting references both macroeconomic outlooks and sector-specific regulatory impact models, alongside consulting feedback from multinational partner sites.
There have been notable shifts in intermediate supply, with some upstream plants facing periodic closures for environmental inspections, directly affecting both lead time and raw material pricing. Increased preference among EU buyers for locally certified batches, driven by concern over global supply chain disruptions, is recalibrating spot market dynamics.
Implementation of ICH Q3D (Elemental Impurity) guidelines in expanding categories now requires additional routine batch verification for many export destinations. Stricter enforcement of export precursor documentation under new Chinese regulations impacts shipment timing, particularly on short notice or urgent delivery requests. EU importers seek enhanced data transparency for impurity and solvent residue profiles.
Manufacturing teams have increased process audit frequency across supplier sites, prioritizing continuous verification of in-process controls to minimize compliance interruption risk. Expanded multi-source procurement and local final packaging operations aim to hedge shipping delay exposure. Product release schedules incorporate rolling batch testing, keeping buffer stock ready for rapid regional reallocation if regulatory challenges emerge.
Cefuroxime Axetil is produced in multiple pharmaceutical grades due to its role as a second-generation cephalosporin oral prodrug, primarily supplied to the finished dosage manufacturers of antibacterial drugs. Demand centers around several major application fields:
| Application | Preferred Grade Characteristics | Critical Parameters |
|---|---|---|
| Direct Compression Tablets | Optimized particle size distribution, controlled polymorph ratio, moderate residual moisture, low flow agent addition | PSD (d10, d50, d90), X-ray polymorph fingerprint, water content |
| Wet Granulation Tablets | Finer primary particle, controlled agglomeration, enhanced surface area, rigorous solvent residue control | Particle size, residual solvents, surface area |
| Oral Suspensions | Consistent re-dispersibility, minimal caking, high chemical purity, uniform micronization | Particle size, agglomerate fraction, related substances |
| Development & Custom Batches | Tailored PSD, experimental controls, extended CoA detail on batch history | Batch traceability, customizable test parameters |
The final suitability of any batch involves cross-verifying several production and quality control factors that directly affect downstream results:
Begin by clarifying whether the target is oral solid, oral suspension, or laboratory-scale R&D. The manufacturing department keeps historical data on grade performance in each major application. A full understanding of the downstream processing method helps inform the granularity, dryness, and bulk handling strategy for the API.
Review which pharmacopeia (e.g., EP, USP, JP, or national standard) applies, as release testing and impurity profiling will shift according to region. Regulatory compliance determines not just final release, but also permitted synthesis auxiliaries, solvents, and process aids during batch production. Requests outside common regulatory standards may require additional documentation or batch-specific validation.
Some dosage forms tolerate higher levels of specific minor impurities due to their formulation buffer or presence of protective excipients, while pediatric and high-potency formulas almost always demand lower impurity profiles. The technical department recommends matching API grade impurity specifications to the strictest element in the finished drug product requirement.
Large-scale production lots benefit from streamlined grades with fewer customizations to ensure batch consistency. Smaller or clinical-scale R&D may justify custom micronization or tailored impurity testing for a premium. Batch size also influences internal batching logic and risk assessment by production and quality teams.
Testing a production-sourced representative sample supports confirmation of technical fit based on the customer’s downstream process. The technical service team documents both in-process control and post-release batch data to facilitate qualification in customer sites. Feedback on fit or observed deviations enables informed grade or process modification.
At the production site, continuous attention goes into the establishment and maintenance of external and internal quality management systems. The facility operates under current pharmaceutical GMP standards. Audits—both regulatory and customer-initiated—cover batch production records, cleaning validation, environmental monitoring, and deviation management. Work instructions and batch documents link directly to real manufacturing steps to ensure traceability. Inspection agencies occasionally require certifications such as ISO 9001 or equivalent; these are maintained through routine surveillance and recertification cycles, reviewed stepwise from incoming raw materials to finished doses.
The manufacturing process for Cefuroxime Axetil is backed by DMF (Drug Master File) filings where applicable. Product compliance focuses on regulatory filings by market, such as US DMF, CEP certification in the EU, and other national submissions. Each market’s requirements create small batch-level variations—traceability and full control of raw material sources are required for every regulatory market supplied. Certificate of Analysis (COA) batches reference validated analytical methods and established product release protocols. Audits specifically focus on impurity profiling, residual solvents, and microbial control strategies tied to each market registration.
Document support extends beyond a COA. Typical deliverables include batch manufacturing records, method validation summaries, impurity characterizations, and, where requested, full regulatory dossiers. These documents rely on production records that hold information on process time stamps, equipment cleaning, and in-process sampling. Certificates and reports are only provided against specific batch numbers, always referenced to active manufacturing campaigns. If out-of-spec or atypical events arise, incident and deviation reports, risk assessments, and corrective actions are documented and retained per regulatory holding periods.
Routine Cefuroxime Axetil production runs are scheduled according to rolling demand forecasts and established customer annual contracts. The site’s core reactors, downstream workup, and granulation suites operate on a campaign-rotation model. Priority supply agreements support both stable, high-volume pharmaceutical clients and contract formulations for development projects with unpredictable offtake. Minimum order quantities and lead-times depend on batch size, specification, and grade—adjustable for multi-market launches and pilot formulation runs. Rolling forecasts from repeat clients guide intermediate and finished product scheduling; rapid slotting is possible by leveraging parallel production lines.
Key process scale is anchored to the installed reactor capacity and validated downstream purification modules. Long-term procurement and vertical integration of starting materials limit risk of upstream interruption. Any scale-out or process-intensification efforts are strictly managed by technical transfer protocols and advance notice periods agreed with clients. Batch-to-batch consistency is routinely charted—focus issues include yield fluctuations due to seasonal variability in raw material quality and any deviation in critical process parameters at reaction/purification steps. The feedback from real production runs drives process improvements to ensure release criteria remain robust.
Sample requests follow a traceable application workflow. Prospective partners—whether development-phase clients or finished dosage manufacturers—may apply for evaluation samples. Each request must specify intended use, preferred grade, and any special analytical criteria. The technical department assigns a dedicated project number; retained sample inventory supports re-analysis if necessary. All shipped samples reference internal control batch records and carry draft documentation, including a pre-release COA and real process histories. For stability, impurities, or dissolution questions, the technical team provides raw data and method protocols on demand.
Procurement models range from fixed-quantity annual offtake with scheduled call-offs, to framework agreements for split shipments matching project stage needs. Some partners require joint technical transfer for formulation work—here, rapid change management in response to analytical or regulatory queries is essential. The commercial and supply chain teams review variance in order quantities, adjust minimum order lots as projects evolve, and set up supply chain risk buffers based on forecast volatility. Custom synthesis or intermediate purification steps may be negotiated as part of a broader project support plan; every variation is tracked to technical agreements with explicit specification reconciliation at the QA/QC interface.
Manufacturing of Cefuroxime Axetil demands a balanced integration of process yield, impurity control, and regulatory compliance. Ongoing projects in process chemistry focus on reducing critical impurities, particularly axetil-related and cephalosporin-core degradants, through route optimization and advanced purification. Raw material traceability and intermediary stability remain focal areas as increasing global regulatory scrutiny brings raw-to-batch identity and reproducibility into sharper focus.
Development efforts extend beyond oral solid dosage forms into pediatric suspensions and fixed-dose combinations. Demand grows in regions with evolving antimicrobial resistance profiles, encouraging manufacturers to explore extended-release matrices and novel excipient blends to improve adherence and pharmacokinetics. Formulation scientists increasingly collaborate with clinical teams to match material grades with patient and region-specific dissolution and bioavailability demands.
Synthesis at scale continues to present challenges in selective acylation, moisture-sensitive step handling, and minimization of residual solvents. Handling cephalosporin cores under controlled humidity, especially at large volumes, tests containment and occupational safety protocols. Continuous improvements in in-process analytics—such as real-time HPLC monitoring for key intermediates—help reduce batch-to-batch deviation. Adoption of green chemistry, such as solvent recycling and energy-efficient crystallization, provides incremental technical relief but still requires close oversight given the cephalosporin core's sensitivity to hydrolysis and oxidation.
Global demand for oral beta-lactams steadily rises as resistance management and access programs in emerging markets expand. Cefuroxime Axetil maintains a moderate growth trajectory, tied to vaccine introduction timelines, antimicrobial stewardship commitments, and the pace of generic regulatory approvals. Demand for differentiated grades—optimized for suspension, high-potency, or stability-enhanced formats—exceeds growth in standard bulk volumes.
Process intensification is a clear trend: manufacturers invest in more compact, automated equipment to reduce material waste and environmental load. Upstream automation, closed-transfer of moisture-sensitive intermediates, and real-time release analytics support consistent output at scale. New analytical methods arise for faster impurity profiling and stability prediction, allowing for faster batch release and more granular customer-specific quality agreements.
Environmental performance has shifted from project aspiration to customer-driven requirement. Solvent recovery units, byproduct valorization, and integration of renewable utilities form central pillars for any license renewal or long-term supply agreement. Achieving lower water and energy footprints, especially in drying and crystallization steps, forms part of annual operational targets. Process waste streams and air emissions are closely tracked, and continuous improvement projects focus on recovering or safely converting side products.
Direct technical dialogue begins with detailed discussion of the specific formulation route or processing requirement. Engagement always includes the manufacturer’s QC and process teams, who support customers in analyzing impurity spectra, API-excipient compatibility, and dissolution profiles under stress conditions. The support team reviews customer-specific analytical concerns, assists in transfer protocols, and documents all batch-dependent outliers to support regulatory filings.
Feedback from formulation stages routinely drives raw material requalification and process parameters adjustment. Technical experts provide practical input on granulation, blending, and compressibility; suggest grade switches or particle size refinements for fluid-bed or direct-compression processing. Pilot-scale data from development customers is shared, with structured root-cause analysis meetings arranged for any observed performance deviation. Application teams collect stability data in real-time to support shelf-life projections for individual customer projects.
Support does not end with product delivery. The manufacturer’s QA and logistics teams maintain traceable records for each batch dispatched, ensuring rapid investigation and resolution if a downstream event arises. Each after-sales request triggers formal CAPA evaluation within the production system. Response teams maintain full access to batch history, raw material lot data, and deviation logs to provide rapid and transparent investigation outcomes. Long-term bioequivalence and impurity trend reporting is available for customers participating in multi-year supply partnerships.
As a direct producer of Cefuroxime Axetil, our facility manages every stage of synthesis and quality oversight in-house. Full integration gives us clear command over raw material sourcing, in-process controls, and the final isolation. Our technical team adapts process parameters with every batch, drawing from experience rather than routine. This commitment results in material that meets strict pharmacopoeial thresholds, with particle characteristics and residual solvent levels tracked well below regulatory limits.
Bulk Cefuroxime Axetil moves primarily into the formulation of oral solid dosage forms for regulated and semi-regulated pharmaceutical markets. Multinational and regional generic manufacturers rely on industrial-scale output for high-volume tableting and encapsulation. This substance forms the cornerstone of prescription antibiotics deployed in hospitals and clinics worldwide. We understand downstream formulation requirements, and our material demonstrates compatibility in direct compression, wet granulation, and coating processes without causing technical hurdles for end users.
Batch records trace every movement inside the plant, alongside continuous monitoring by analysts trained on dedicated equipment. We minimize process drift through automated sampling and target purities beyond the compendial benchmark. With each release, results from multiple validated methods confirm identity and assay, and impurity profiles are tightly constrained. Repeat customers cite this reproducibility as critical, especially where large-scale drug production demands seamless integration and stable physical properties across annual contracts.
Packaging operations take place inside climate-managed zones connected to our synthesis floors. All Cefuroxime Axetil leaves our gate in inert-lined fiber drums, sealed to block moisture ingress and loss of potency. Automated weight checks and serialized labels tie every outbound shipment to origin batch data. This approach protects the cargo during international transit, supports port clearance requirements, and lowers risks around handling at formulation plants. Our logistics unit operates at container scale, fulfilling standing orders and urgent calls across regions. Customers gain shipment flexibility—whether sourcing for monthly blending schedules or responding to market upswings within tight lead times.
Manufacturers, purchasing teams, and production managers regularly consult our product engineers to optimize secondary processing. We provide documentation on compatibility, impurity carryover, and stability, cutting through generic answers to solve specific plant bottlenecks. If a film-coating operation reports capping or sticking, our team reads full audit trails, examines particle morphology, and shares root cause analysis grounded in direct runs and track record. This collaborative model shrinks downtime for tableting lines and unlocks higher yields for commercial production.
Operational transparency eliminates uncertainties in bulk purchasing. Decision-makers on the buy side gain predictable volume, on-time delivery, and a single processing logic from initial order to factory floor. Cost efficiencies stem from scale, direct negotiation, and proactive risk management on both sides. Our structure favors multi-year projects and long-term alliances, giving all partners leverage to forecast and budget in a changing market environment. Procurement professionals prioritize assurance of supply, and pharmaceutical producers trust real control over batch variability—key factors we uphold at production level.
Cefuroxime Axetil tablets require well-maintained storage conditions to retain expected stability from production to final use. Over the years, our team has observed that small deviations in storage temperature can accelerate hydrolysis and degradation, directly affecting quality from tablet uniformity down to potency. As a direct manufacturer, we test retention samples under the same ranges we specify to clients, because confidence relies on practice, not just on documentation.
Our process keeps a close watch on temperature from the packaging line until finished product batches are released. Cefuroxime Axetil tablets preserve best stability in a controlled room environment, between 20°C and 25°C. This range is reflected in both regulatory submissions and our validation reports. Within this band, active ingredient breakdown stays negligible over intended shelf life. Wide swings outside this scope — such as prolonged storage above 30°C — can cause discernible tablet discoloration, possible loss of bioactive compound, and difficulties with dissolution rates during later analytical checks.
Many customers operate warehousing facilities across various climates. We have seen firsthand how hot or humid conditions, even for short periods, can compromise moisture-sensitive products like Cefuroxime Axetil. Packaging controls such as desiccants and blister foils help, but nothing substitutes for maintained room temperature. Long-term exposure to elevated heat ramps up risk of axetil hydrolysis and generates impurities that would trigger regulatory recalls if discovered during routine lot testing.
In our facility, Cefuroxime Axetil tablets move directly into foil blisters at the primary packaging stage. This step minimizes risk of air or humidity ingress. Standard secondary cartons are then palletized with lot tracking for clear traceability. Our logistics policy relies on temperature-monitored warehousing and vehicles equipped to maintain controlled ambient conditions. Over the years, routine audits have shown that when clients align their storage practices with our recommendations, tablets retain no more than baseline changes as confirmed by ongoing stability samples.
Deviation reports and stability studies from our own product lines confirm the risk: temperatures above 30°C, even for a few days, speed up degradation pathways. Regulatory authorities require corroborating stability data at various ICH storage conditions. Our files demonstrate Cefuroxime Axetil tablets show maximum shelf stability at 20°C to 25°C, and significant loss beyond 30°C in accelerated trials. Recognized authorities recommend these same conditions, but our own finished goods monitoring supports them with real-life results.
Our technical team emphasizes that keeping Cefuroxime Axetil tablets at the prescribed 20°C-25°C storage range is not a suggestion — it is a key requirement for stable, compliant finished product. We provide documentation and process support to help customers implement temperature controls in line with our own practices. Experience shows this attention to detail underpins product longevity and regulatory confidence. Any facility handling this active should use calibrated monitoring and alert systems to prevent accidental exposure to heat or high humidity.
By sharing practical experience and continuous monitoring data, we extend assurance well beyond standard packaging or leaflet recommendations. Consistent temperature control stands as the best defense against degraded material, product returns, and regulatory interruptions.
In the pharmaceutical field, certainty and consistency matter more than claims. As a direct manufacturer of Cefuroxime Axetil, we know customers expect more than just a raw material—they expect reliable batch planning, scalable fulfillment, and honest discussion about our production constraints and capabilities.
Production efficiency and product integrity both hinge on the size of each run. For Cefuroxime Axetil, our minimum order quantity (MOQ) typically starts at 50 kilograms. Below this threshold, widespread cleaning, validation, and logistic costs make commercial manufacturing impractical. This MOQ allows us to maintain rigorous controls, minimize foreign matter risk, and ensure every shipment upholds consistent quality standards. Larger quantities generally streamline processing and reduce lot-to-lot variability, which is especially critical for active pharmaceutical ingredients bound for regulated markets.
Bulk buyers often demand custom packing or specific particle size. Our MOQ keeps the line moving so our technical team stays focused on quality, not small-batch packaging changes. For custom specifications or tighter tolerances, higher MOQs may apply, and our team evaluates feasibility based on available equipment and ongoing batch schedules.
Forecasting and scheduling go hand in hand. For orders at our standard MOQ, the production-to-delivery lead time usually falls between 4 and 8 weeks. This window covers everything from raw material sourcing, validated batch production, in-process testing, and stringent release procedures before delivery. Fluctuations in lead time arise as a direct result of global raw material flows, regulatory inspections on site, or periods of elevated demand. Our commitment includes transparent timelines and proactive order management so clients can align their inventory and production schedules with minimal disruption.
Repeated, forecasted orders—especially annual supply agreements—grant us the ability to reserve capacity and allocate critical starting materials before bottlenecks develop. In turn, our regular clients benefit from shorter, more predictable delivery cycles, and we avoid the costly delays brought on by unexpected changes in market conditions or regulatory requirements.
APIs like Cefuroxime Axetil demand more than just quantity and promptness. Regulatory compliance shapes every production run. Our batch records, validated analytical methods, and technical documentation flow seamlessly with every shipment, so downstream formulation and registration go forward without avoidable holdups. Our technical team maintains open channels with procurement, supply chain, and R&D teams to solve issues such as qualification batches, process changes, or technical clarifications quickly—sometimes even before orders hit our production floor.
Our facilities operate at GMP-compliant standards. Each batch passes through multi-stage testing—microbial limits, residual solvents, polymorphism, and consistent potency assays. As a rule, we do not ship unfinished or untested material. This discipline supports our reputation and reinforces trust among formulation plants and regulatory auditors worldwide.
Large-scale pharmaceutical supply chains run on honest dialogue, not marketing promises. Our minimum order quantity and lead time figures reflect what we can deliver without compromise. We keep communication direct: project managers, production planners, and QC teams work closely with every client to solve supply chain concerns as partners, not as brokers in the middle.
Regulatory compliance defines our daily operations, especially when managing the export and import of antibiotics like Cefuroxime Axetil. As a pharmaceutical manufacturer, we recognize the seriousness of international shipping frameworks and the documentation required for antimicrobials. Our experience informs both our workflow and our communication with international partners striving for guaranteed access, efficiency, and regulatory correctness.
Cefuroxime Axetil, classified within the pharmaceutical category, must follow international transit standards and local authority regulations in both source and destination territories. We consistently prepare export documentation that generally includes Certificate of Analysis, Certificate of Origin, commercial invoice, and, when required by destination markets, a Good Manufacturing Practice (GMP) certificate or Drug Master File (DMF) reference. Customs authorities may request import permits from the buyer's national drug regulator, especially in countries with stricter antimicrobial controls. Transparency in paperwork prevents shipment delays and customs queries, both of which we address upfront before consignment dispatch.
Cefuroxime Axetil does not appear on the majority of global lists designating chemicals as hazardous for air, marine, or ground transport. Based on our review of IATA, IMDG, and ADR guidelines, this product travels under standard non-hazardous classification. Nevertheless, as a manufacturer, we adhere strictly to required labeling, batch coding, and supply all necessary MSDS or SDS in English and, where necessary, in the language of the receiving country. For sensitive pharmaceutical substances, including antibiotics, this approach remains vital for logistics and for regulatory inspection at transit points.
Each market enforces its own drug import regulations. Some jurisdictions restrict antibiotic volumes or require pre-registration of drug products before clearance. Our export office keeps updated records on partner country guidelines, collaborating closely with consignee import departments to secure LCs, import licenses, and certificates required by local drug authorities. Timely supply pivots on confirming documentation before our production line schedules a shipment slot. This real-time approach shortens lead times and reassures partners expecting urgent clinical supply or finished formulations for further processing.
Traceability remains a central component in drug manufacturing and distribution. Our packing includes batch and lot numbers on both primary and secondary packaging. We maintain electronic records for every consignment, enabling full trace-back for customs inquiries or pharmacovigilance reporting. If regulatory scenarios shift, such as amendments to import quotas or changes in antimicrobial stewardship protocols, we mobilize responsible documentation rapidly using our existing compliance database.
Logistics teams within our plants track international legislation, adapting shipping practice where nations require pre-shipment inspection or additional regulatory paperwork. We monitor global regulatory discussions, especially those relating to antimicrobial resistance and anti-counterfeit controls. In select markets, our technical staff can provide product information in support of registration dossiers or customs requirement clarifications.
Our direct control over production and shipping provides customers with regulatory confidence and supply chain security. We continue to invest in pipeline transparency and documentation readiness, ensuring Cefuroxime Axetil crosses borders effectively and legally in every market where quality antimicrobials serve critical needs.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
